Safety, Tolerability and Pharmacodynamics of SYNB1353 in Healthy Adult Volunteers
Status:
Recruiting
Trial end date:
2023-01-31
Target enrollment:
Participant gender:
Summary
This is a Phase 1, double-blind (Sponsor-open), placebo-controlled, randomized,
dose-escalation, inpatient study using a multiple-ascending dose (MAD) design to assess the
safety, tolerability, and PD of SYNB1353 in HVs.